What is the CanAssist Breast test?

CanAssist Breast is a prognostic test that helps predict the risk of breast cancer recurrence and supports oncologists in personalizing treatment plans.

How accurate is the CanAssist Breast test?

CanAssist Breast has been validated on South Asian and Caucasian populations, demonstrating high accuracy in predicting recurrence risk.

Breast Cancer Recurrence Test, CanAssistBreast, India

Q: Who can benefit from the CanAssist Breast test?

It is suitable for patients diagnosed with early-stage, hormone receptor-positive breast cancer to determine their recurrence risk.

San Antonio Breast Cancer Symposium (SABCS) 2025

Events and Conferences

December, 2025

How does proteomics-based prognostic testing compare to genomic tests and online clinical risk prediction tools in early breast cancer patients?

View

ISO-ISMPO

Events and Conferences

October, 2025

CanAssist Breast: India’s Solution to Prognostication in HR+/HER2- EBC patients.

View

Clinical Breast Cancer

Scientific Publication by OncoStem

August, 2025

CanAssist Breast provides additional insightful prognostic information in retrospective, pooled secondary analysis in clinically low/ high-risk patients with HR+/HER2- EBC

View

Scientific Reports

Scientific Publication by OncoStem

August, 2025

Real-world data of CanAssistBreast- first immunohistochemistryand AI-based prognostic test

View

ESMO Breast

Events and Conferences

May, 2025

Concordance of CanAssist Breast with Oncotype Dx and Mammaprint in Patients with Early-Stage Hormone Receptor Positive Breast Cancer

View

Therapeutic Advances in Medical Oncology

Scientific Publication by OncoStem

May, 2025

CanAssist Breast-based prognostication in low-intermediate estrogen receptor positive (ER1%–20 %) early-stage breast cancer patients helps guide treatment decisions.

View

BreastPath Connect 2025

Events and Conferences

May, 2025

Advancing Insights in Breast Pathology

View

Scientific Publications